The €115 million grant, titled Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials), will increase our understanding of autism and help develop new therapies to improve health outcomes and quality of life for autistic people.
The consortium is academically led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, and involves the Oxford Translational Molecular Neuroscience Group (Nuffield Department of Clinical Neurosciences).
Associate Professor Zameel Cader, Nuffield Department of Clinical Neurosciences commented: 'The Oxford Translational Molecular Neuroscience Group will undertake the stem cell disease modelling for this consortium to understand gene/environment interactions in autism. The goal is to identify biomarkers and targets that may enable stratified clinical trials and personalised medicine in autism.'
Find out more (Nuffield Department of Clinical Neurosciences website)